Duhao Net

Duhao Net helps individual entrepreneurs and enterprises find high-quality suppliers, reduce procurement costs, and make transactions easier.

Jiangsu Lianhuan Pharmaceutical Co., Ltd.: A innovative chemical drugs supplier

Release time：2025-06-27 21:11:21 Source：DuHao

Contact Us Today

Tel : +86 0514-82778972

Email: net.fei@163.com

Address: No. 9, Jiankang 1st Road, Bio-Health Industrial Park, Yangzhou, Jiangsu, China.

Jiangsu Lianhuan Pharmaceutical Co., Ltd. is a national high-tech enterprise specializing in the R&D, production, and sales of chemical drugs. Established on February 22, 2000, and listed on the Shanghai Stock Exchange Main Board (March 19, 2003), the company traces its origins to Yangzhou Pharmaceutical Factory (founded in 1958). Headquartered at No. 9, Jiankang 1st Road, Bio-Health Industrial Park, Yangzhou, Jiangsu, it operates as an integrated pharmaceutical leader with 3 high-tech enterprises and 2 provincial "specialized and innovative" enterprises under its umbrella.

Business & Product Portfolio

The company’s revenue structure comprises:

  • Tablets (49.32%)

  • Medical Devices (24.80%)

  • APIs (12.95%)

  • Injections (4.02%)

  • Others (8.64%)

Key Product Series:

  1. Urinary System: Aprelet (national Class I new drug), Terazosin, Drotaverine HCl injection.

  2. Antihistamines: Ebastine (Class II new drug), Terfenadine, Cetirizine HCl.

  3. Cardiovascular: Felodipine, Simvastatin, Amlodipine maleate.

  4. Steroid Hormones: Prasterone Sulfate Sodium, Danazol.

  5. Antibiotics: Azithromycin, Doxycycline, Roxithromycin.

API Products: Hydrocortisone, hydrocortisone acetate, and levonorgestrel are exported to North America, Europe, Southeast Asia, and Australia, passing FDA inspections since 1984.

Production Capacity & Certifications

  • 10 intelligent production lines for tablets, capsules, suppositories, and granules (5 billion units/year).

  • 4 small-volume injection lines (500 million units/year).

  • 20+ GMP-certified API lines, with FDA-compliant quality systems.

Innovation & R&D Strengths

  • R&D Platforms: 6 provincial engineering centers, academician/doctoral workstations, and collaborations with Shanghai Institute of Pharmaceutical Research, Chinese Academy of Sciences, and China Pharmaceutical University.

  • Pipeline: 100+ projects, including 10+ innovative/improved drugs (1 in Phase III, 1 in Phase I, 1 IND accepted).

  • Talent: 200+ R&D team (10+ PhDs), focusing on cardiovascular, respiratory, and antibiotic fields.

  • Intellectual Property: 70+ patent applications, 25 authorized; certified as "National Intellectual Property Demonstration Enterprise".

Honors & Achievements

  • Top 100 Chinese Chemical Pharmaceutical Enterprises

  • National "Two-in-One Integration" Standard Enterprise

  • 2023 World-Class Professional Leading Demonstration Enterprise (First batch in China, second in Jiangsu)

Leadership

  • Chairman: Qian Zhenhua (since 2024), emphasizes safety, innovation, and regional economic collaboration.

  • General Manager: Dr. Niu Ben (Ph.D. in Pharmaceutical Chemistry), advocates long-term R&D investment, boosting annual R&D funding from ¥10M to ¥200M (20x growth).

Vision

Guided by the "Two Concentrations & Three Highs in R&D" strategy, Lianhuan Pharmaceutical commits to high-end generics, innovative drugs, and global market expansion, aiming to be a world-class pharmaceutical leader.

DuHao Net